<p><strong>Pediatric Use</strong>: Safety and effectiveness in pediatric patients below the age of 13 years has not been established. Therefore, Posaconazole is not recommended for pediatric patients less than 13 years of age.<br />
<br />
<strong>Geriatric Use</strong>: No dose adjustment is necessary for geriatric patients.<br />
<br />
<strong>Hepatic Impairment</strong>: Posaconazole should be used with caution in patients with hepatic impairment due to limited clinical experience and the possibility that posaconazole plasma levels may be higher in these patients. Liver function tests should be evaluated at the start of and during the course of posaconazole therapy.<br />
<br />
<strong>Renal Impairment</strong>: No dose adjustment is required in patients with mild (eGFR: 50-80 mL/min/1.73 m2) to moderate renal impairment (eGFR: 20-49 mL/min/1.73 m2). Patients with severe renal impairment should be monitored closely for breakthrough fungal infections.</p>